Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03463252
PHASE2/PHASE3

Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC

Sponsor: West China Second University Hospital

View on ClinicalTrials.gov

Summary

Primary end points: This clinical trial is aimed to analyze the effectiveness of Levonorgestrel-Releasing Intrauterine System (LNG-IUS, Mirena®) in the fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma, including pathology response and pregnancy outcome. Second end points: To analyze the appearances of side-effects.

Official title: Value of Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Fertility-preserving Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Carcinoma

Key Details

Gender

FEMALE

Age Range

Any - 40 Years

Study Type

INTERVENTIONAL

Enrollment

224

Start Date

2018-04-01

Completion Date

2030-12-30

Last Updated

2021-09-13

Healthy Volunteers

No

Interventions

DRUG

Progesterone

MPA oral 250mg-500mg qd for 3 months per cycle

DEVICE

Mirena®

levonorgestrel intrauterine sustained release system (LNG-IUS) placed in uterus for 3 months per cycle

DRUG

GnRH agonist

GnRH-a intramuscular injection 3.75mg once a month for 3 months per cycle

Locations (1)

West China Second University Hospital

Chengdu, Sichuan, China